Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz

Journal of Addiction Medicine

Volumn 7, Issue 4, 2013, Pages 264-270

  McCance Katz, Elinore F ^a   Gruber, Valerie A ^a   Beatty, George ^b   Lum, Paula J ^b   Rainey, Petrie M ^c  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alcohol; Drug interactions; Efavirenz; HIV infection; Ritonavir

Indexed keywords

ALCOHOL; EFAVIRENZ; RITONAVIR;

ADULT; ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPSYCHOLOGY; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ALCOHOL DRINKING; ANTI-RETROVIRAL AGENTS; BENZOXAZINES; DRUG INTERACTIONS; ETHANOL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RITONAVIR; STATISTICS, NONPARAMETRIC;

EID: 84887976144     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318293655a     Document Type: Article

References (25)

1. Bosron WF, Ehrig T, Li TK. Genetic factors in alcohol metabolism and alcoholism. Semin Liver Dis 1993;13(2):126-135.
2. Braithwaite RS, Conigliaro J, Roberts MS, et al. Estimating the impact of alcohol consumption on survival for HIV + individuals. AIDS Care 2007;19:459-466.
3. Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for nonadherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr 2006;43:411-417.
4. Cook RL, Sereika SM, Hunt SC, et al. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001;16(2):83-88.
5. Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther 2002;24(10):1515-1548.
6. Gilead Sciences: Emtriva Package Insert 2012 [Gilead web site]. Available at http://www.gilead.com/pdf/emtriva-pi.pdf. Accessed March 12, 2013.
7. Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr 2009;52(2):180-202.
8. Janssen Therapeutics. Prezista Package Insert 2013 [Prezista web site]. Available at http://www.prezista.com/sites/default/files/pdf/us-package-insert. pdf. Accessed March 12, 2013.
9. Kalichman SC, Amaral CM, White D, et al. Alcohol and adherence to antiretroviral medications: interactive toxicity beliefs among people living with HIV. J Assoc Nurses AIDS Care 2012;23(6):511-520.
10. Kalichman SC, Grebler T, Amaral CM, et al. Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs. J Gen Intern Med 2013;28(3):399-405.
11. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-431.
12. Li X, Chan WK. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv Drug Deliv Rev 1999;39:81-103.
13. Lieber CS. Metabolic consequences of ethanol. Endocrinologist 1994;4(2):127-139.
14. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004;36:511-529.
15. McCance-Katz EF, Kosten TR, Jatlow P. Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either drug alone-a multiple dose study. Biol Psychiatry 1998;44:250-259.
16. McCance-Katz EF, Lum PJ, Beatty G, et al. Untreated HIV infection is associated with higher blood alcohol levels. J Acquir Immune Defic Syndr 2012;60(3):282-238.
17. McCance-Katz EF, Price LH, McDougle CJ, et al. Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior and the role of cocaethylene. Psychopharmacology 1993;111:39-46.
18. Molina JM, Peytavin G, Perusat S, et al. Pharmacokinetics of emtricitabine, didanosine, and efavirenz administered once daily as treatment for HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). HIV Med 2004;5:99-104.
19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed March 14, 2013
20. Perloff ES, Duan SX, Skolnik PR. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005;33:764-770
21. Physician's Desk Reference. Efavirenz (Sustiva) 930-938, 2007.
22. Samet JH, Horton NJ, Meli S, et al. Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res 2004;28:572-577.
23. Scuitto J. Teens in South Africa smoke anti-retroviral drug efavirenz for cheap high [AIDS Health Foundation Web site]. April 8, 2009. Available at: http://www.aidshealth.org/archives/news/no-turning-back-teens-abuse. Accessed January 15, 2013.
24. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP 2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP 2B6 catalytic activity. J Pharmacol Exp Ther 2003;306:287-300.
25. Wechsler D. The Measurement and Appraisal of Adult Intelligence. Baltimore, MD: Williams & Wilkins, 1958.